Natalia Martin Orozco
Chief Scientific Officer Providence Therapeutics
Seminars
Wednesday 22nd July 2026
mRNA-Based Therapeutics for Targeting Neoantigens & Overexpressed Antigens in Children & Young Adults with High-Risk Brain Tumours
3:00 pm
- Introducing the Brain tumor antigen landscape and opportunities for personalized mRNA Therapeutics
- Presenting the PAEDNEOVAX trial phase I/II clinical trial evaluating a personalised mRNA vaccine in children and adolescents with relapsed/refractory brain tumours (including medulloblastoma, ependymoma and high grade glioma) and newly diagnosed Diffuse Midline Glioma (DMG)
- Unveiling the strategy to provide the mRNA therapeutic on time for treatment and preliminary results
